Skip to content
Glycyx logo — Restoring immune response in cancer: reversing Opioid-Induce...

Glycyx

Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunotherapy efficacy

Founded 2020 United States San Francisco, United States 3 employees Series A Total: $7.10M Biopharma, Biotechnology +1

General Information

Company Name Glycyx
Founded Year 2020
Location United States San Francisco, United States
Employees 3
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Glycyx. To contact Glycyx, visit glycyx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Glycyx compare?

A PDF of Glycyx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Glycyx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Glycyx

Glycyx, a highly innovative biotech firm founded in 2020 and headquartered in the United States, is tackling a critical yet often overlooked challenge in cancer treatment—opioid-induced immunodeficiency that diminishes the efficacy of immunotherapy. Known as Opioid-Induced Immunotherapy Failure (OIIF), this condition is addressed through Glycyx's pioneering approach.

With their slogan, "Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunotherapy efficacy," Glycyx is positioned at the intersection of biopharma, biotechnology, and pharmaceutical industries. Their novel small molecule, axelopran, is developed to counteract opioids’ immunosuppressive effects without sacrificing pain relief. It is designed to bolster immune checkpoint inhibitor (ICI) therapies as a combination solution, enhancing cancer treatment options.

This promising therapy is now Phase 2 ready with established safety credentials and demonstrated preclinical efficacy. Following a successful $3.50M Series A investment as of 01 July 2023, Glycyx is strategically positioned to revolutionize cancer treatment paradigms and greatly improve both survival rates and quality of life for cancer patients worldwide.

Business keywords: Cancer Treatment, Immunotherapy, Opioid-Induced Immunodeficiency, Immune Checkpoint Inhibitors, Peripherally Restricted Opioid Antagonist, Phase 2 Clinical Trials, Tumor Microenvironment, Non-Small Cell Lung Cancer, Head and Neck Cancer, Hepatocellular Cancer, Immuno-oncology, Therapeutics, Oncology, Clinical Development

Services & Products

Development of therapies that restore immune function
Combination treatments with immune checkpoint inhibitors
Enhanced T-cell infiltration into tumors
Inhibition of opioid-induced immune suppression

Target Customers

Cancer patients Healthcare providers Oncologists Pharmaceutical companies

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $3.50M -
01 Jul 2023
Seed $600.00K -
01 Jan 2022
Seed $3.00M -
01 Jun 2020

Glycyx Alternatives & Competitors

View All Alternatives
Glycyx vs

Developing next-generation targeted cancer immunotherapy treatments

Series B
50 employees
Biopharma, Health Care
Glycyx vs
3T Biosciences
3T Biosciences United States

3T is an immunotherapy company developing next-generation, transformative therapies for broad patien...

Series A
26 employees
Biopharma, Biotechnology
Glycyx vs
Onchilles Pharma
Onchilles Pharma United States

Developing drug candidates that have the potential to be broadly effective against a wide range of c...

Series B
10 employees
Biopharma, Biotechnology

FAQ About Glycyx

Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunotherapy efficacy
Glycyx was founded in 2020.
Glycyx is headquartered in San Francisco, United States.
Glycyx operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Cancer Treatment, Immunotherapy, Opioid-Induced Immunodeficiency and Immune Checkpoint Inhibitors. Its customers include Cancer patients, Healthcare providers and Oncologists.
Glycyx has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Glycyx has approximately 3 employees.
Glycyx has completed 3 funding rounds, raising a total of $7.10M. The latest funding stage is Series A.
Glycyx offers: Development of therapies that restore immune function, Combination treatments with immune checkpoint inhibitors, Enhanced T-cell infiltration into tumors, Inhibition of opioid-induced immune suppression.
Top alternatives and competitors to Glycyx include iOmx Therapeutics AG, 3T Biosciences, Onchilles Pharma, Xilio Therapeutics, Inc., Prokarium. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Glycyx and iOmx Therapeutics AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Glycyx, https://bouncewatch.com/company/glycyx, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout